Mycamine(micafungin)
Micafungin, Mycamine (micafungin) is a small molecule pharmaceutical. Micafungin was first approved as Mycamine on 2005-03-16. It is used to treat candidemia and mycoses in the USA. It has been approved in Europe to treat candidiasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Micafungin, Mycamine (discontinued: Micafungin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| micafungin | ANDA | 2024-10-09 |
| micafungin in sodium chloride | New Drug Application | 2023-09-29 |
| micafungin sodium | ANDA | 2022-07-28 |
| mycamine | New Drug Application | 2022-08-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| candidemia | EFO_1001282 | D058387 | — |
| mycoses | — | D009181 | B35-B49 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Candidiasis | D002177 | — | B37 | 3 | 5 | 10 | 6 | 3 | 26 |
| Mycoses | D009181 | — | B35-B49 | 4 | 5 | 6 | 6 | 4 | 25 |
| Invasive candidiasis | D058365 | EFO_1001283 | B37 | 3 | 3 | 5 | 4 | 3 | 18 |
| Invasive fungal infections | D000072742 | — | — | — | 3 | 2 | 5 | 5 | 15 |
| Candidemia | D058387 | EFO_1001282 | — | 2 | 2 | 4 | 3 | 2 | 13 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | 4 | 2 | 3 | — | 9 |
| Infections | D007239 | EFO_0000544 | — | — | — | 3 | 2 | 3 | 8 |
| Neutropenia | D009503 | — | D70 | 1 | 2 | — | 3 | 1 | 7 |
| Communicable diseases | D003141 | — | — | — | — | 2 | 1 | 2 | 5 |
| Fever | D005334 | HP_0001945 | R50.9 | 1 | 1 | — | 1 | 1 | 4 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | — | 2 | — | — | 2 |
| Fungemia | D016469 | — | B49 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 1 | 1 | — | — | — | 2 |
| Acute disease | D000208 | — | — | — | 2 | — | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | — | 1 |
| Meningitis | D008581 | HP_0001287 | G03 | — | 1 | — | — | — | 1 |
| Fungal meningitis | D016921 | EFO_1000942 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stem cell transplantation | D033581 | — | — | 1 | — | — | — | — | 1 |
| Catheter-related infections | D055499 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Bone marrow transplantation | D016026 | — | — | 1 | — | — | — | — | 1 |
| Immunocompromised host | D016867 | — | D84.9 | 1 | — | — | — | — | 1 |
| Candida | D002175 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 1 | 1 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Micafungin |
| INN | micafungin |
| Description | Micafungin is a cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy. It has a role as an antiinfective agent. It is an echinocandin and an antibiotic antifungal drug. |
| Classification | Small molecule |
| Drug class | antifungal antibiotics (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 235114-32-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL457547 |
| ChEBI ID | 600520 |
| PubChem CID | 477468 |
| DrugBank | DB01141 |
| UNII ID | R10H71BSWG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,060 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,074 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use